Fengman Tincture Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is a concentrated ethanolic botanical extraction supplied as a multi-dosage-form active pharmaceutical ingredient. The product designation does not represent a single physical formulation, but rather a standardized tincture that downstream manufacturers process differently according to the intended route and dosage form. Release documentation for the veterinary grade typically includes assay of marker compounds by high-performance liquid chromatography against a manufacturer reference standard, ethanol content determined by gas chromatography, residual solvent limits aligned with ICH Q3C, elemental impurities evaluated according to Ph. Eur. 2.4.20 or USP <232>/<233>, and microbiological quality assessed under Ph. Eur. 5.1.4. Because a harmonized pharmacopeial monograph for this exact tincture is not available in the current editions of Ph. Eur., USP–NF, or VICH GL11, the manufacturer’s specification file and certificate of analysis function as the primary control documents. For injectable applications, the tincture must be subjected to additional solvent reduction, endotoxin control, and particulate filtration before formulation.

What specification controls define the veterinary API before formulation-specific processing?

The release specification for Fengman Tincture Veterinary Grade API is organized around identity, assay, purity, residual solvent, elemental impurity, and microbial limits. The ethanolic matrix is typically controlled within 40.0–70.0% v/v ethanol, with water content at or below 30.0% w/w. Methanol is limited to 0.10% v/v or less using Ph. Eur. 2.2.28. Heavy metals may be reported as not more than 20 ppm by Ph. Eur. 2.4.8, with arsenic not more than 2 ppm, cadmium not more than 1 ppm, lead not more than 5 ppm, and mercury not more than 0.1 ppm where regional veterinary registration files require the full elemental profile. Total ash is controlled below 2.0%, and acid-insoluble ash below 0.5%. Microbiological limits for oral and premix applications follow Ph. Eur. 5.1.4 category 3B, with total aerobic microbial count not exceeding 10³ CFU/g or mL, total combined yeast and mould count not exceeding 10² CFU/g or mL, and absence of Escherichia coli and Salmonella in 10 g or 10 mL. For injectable-grade processing, the final solution must also meet bacterial endotoxin limits under Ph. Eur. 2.6.14; the threshold is generally below 0.5 EU/mg of solid extract after ethanol removal.

Storage conditions for the unprocessed tincture are defined by the ethanol-water matrix and the oxidative sensitivity of polyphenolic constituents. The product should be held in sealed, light-resistant containers at or below 25°C. Once a container is opened, the manufacturer’s stability data typically require use within 30 days under continuous nitrogen blanketing because repeated headspace exposure increases peroxide-related marker loss. Consignments exposed to temperatures above 35°C for more than 72 h should be re-assayed before use in injectable batches. Published data for this specific configuration is limited; therefore, downstream stability of the finished dosage form requires confirmation under VICH GL3 and GL5 conditions for the target veterinary species and climate zone.

In oral solid dosage manufacturing, the tincture is frequently adsorbed onto a carrier before blending. Because the liquid contains both water and ethanol, direct addition to a tablet granulation vessel can produce local overwetting and non-uniform binder distribution. A high-shear granulator with impeller speed in the range of 150–300 rpm and chopper speed of 1000–3000 rpm is used after the tincture has been pre-mixed with a portion of the diluent. Drying of the wet mass is performed in a fluid-bed dryer with inlet air temperature not exceeding 60°C, because higher temperatures accelerate degradation of thermolabile marker compounds and produce darkening of the granule surface. The dried granulate is milled through a 1.0 mm screen and lubricated with magnesium stearate at 0.5–1.5% w/w before compression. Tablet hardness is maintained between 50 N and 150 N to avoid lamination while preserving disintegration under Ph. Eur. 2.9.1.

If the same tincture is assigned to injectable solutions, where do ethanol, endotoxin, and particulate boundaries become process-limiting?

Injectable application of the tincture is not a direct dilution step. The ethanol concentration in the supplied tincture is far above the acceptable limit for most parenteral veterinary formulations; therefore, ethanol must be removed by vacuum distillation, rotary evaporation, or tangential flow filtration. A wiped-film evaporator operating under reduced pressure can reduce ethanol to below 0.5% v/v in the concentrated extract, but the evaporation jacket temperature should remain below 45°C to protect marker integrity. After ethanol removal, the residual aqueous concentrate is dissolved or dispersed in a suitable vehicle and adjusted to a pH range of 4.5–7.0, depending on the stability of the marker compounds and the buffering capacity of the formulation. The solution is clarified through 0.45 µm and 0.22 µm filters before filling. Terminal sterilisation is feasible only if the formulation has been shown to withstand 121°C for 15 min without assay loss exceeding 5.0%. If heat sterilisation is not feasible, aseptic filtration and filling are required, but the resulting product falls outside pharmacopeial definitions of terminally sterilised injectables for some regulatory jurisdictions.

For injectable use, particle matter is controlled according to Ph. Eur. 2.9.19 or USP <788>. Because botanical extracts contain tannins, flavonoids, and other polyphenolic matrix components, pH adjustment can generate particulate agglomerates. The formulation must be evaluated for precipitate formation at 2–8°C, at ambient 25°C, and at 40°C over the intended shelf life. A compatibility screen using Ph. Eur. 2.9.33 for visual inspection and light obscuration particle counting is required. If the injectable grade contains divalent cations, chelation with disodium edetate at 0.01–0.05% w/v may be necessary to prevent metal-polyphenol complexation, but this must be confirmed experimentally because excessive chelator concentration can alter tonicity and antimicrobial preservation.

Finished injectable solutions containing this API should be tested for bacterial endotoxin by the limulus amoebocyte lysate method using Ph. Eur. 2.6.14; the limit is calculated from the maximum dose and species body weight. For a bovine intramuscular formulation administered at 1 mL per 20 kg body weight, the endotoxin limit is typically set below 0.5 EU/mL. Subcutaneous and intravenous products may require stricter limits. Because the tincture itself can mask endotoxin in the undiluted state, the test is performed after ethanol removal and dilution to the final vehicle composition.

Veterinary premix and medicated feed carriers, blend uniformity, and segregation risks

In powders, granules, and premix applications, the tincture is often sprayed onto a solid carrier under low-shear mixing. Suitable carriers include precipitated silica, calcium carbonate, lactose monohydrate, corncob meal, wheat bran, or maltodextrin. The choice of carrier changes the final flowability and dusting potential. In a 600 L horizontal ribbon mixer, coefficient of variation for blend uniformity can be maintained below 5.0% when the tincture is incorporated by geometric dilution in at least 3 sequential stages and the total liquid addition does not exceed 10% w/w of the carrier mass. Higher liquid loading causes clumping and dead zones near the mixer shaft. After blending, the premix is discharged through a 500 µm sieve to remove wet agglomerates and to improve uniformity according to Ph. Eur. 2.9.40.

Segregation after blending is a recognized operational boundary. If the API-bearing carrier has a bulk density below 0.40 g/cm³ and the final feed matrix has a bulk density above 0.65 g/cm³, the active particles may rise during transport and discharge. The use of a densified carrier such as calcium carbonate at 20–40% w/w of the premix reduces this risk. For medicated feed under FDA 21 CFR 558.4 and EU Regulation 2019/4, the premix must be stable during the intended feed pellet conditioning step. Steam conditioning above 75°C for more than 30 s can reduce marker assay by more than 10% in unprotected premix formulations. A protective fat coating applied during post-conditioning vacuum coating may be required for pelleted feed.

When pharmaceutical use replaces feed-grade tincture, what separates this API from single-route botanical extracts?

The primary difference between Fengman Tincture Veterinary Grade API and feed-grade or technical-grade botanical tinctures is the degree of analytical control and the documented suitability for multiple pharmaceutical operations. Feed-grade materials are often released without full residual solvent profiles, endotoxin screening, or batch-to-batch marker standardization. Veterinary API grade material is controlled to registration-supporting specifications, with a certificate of analysis that includes identity, assay, impurities, residual solvents, elemental impurities, and microbial limits. For tableting and encapsulation, the tincture’s ethanol content must be reduced or bound to a solid carrier to avoid die sticking and capsule shell deformation. For premix and powder applications, the residual ethanol can be retained within the carrier if the final drying is completed under 50–60°C. For injectable use, the ethanol must be essentially eliminated and the final solution must meet parenteral particulate and endotoxin standards.

Compared with purified phytochemical active compounds, the tincture contains co-extracted polyphenols, polysaccharides, and nitrogen-containing constituents that can act as viscosity modifiers, hydrogen-bonding binders, and chelating agents. These co-extracted substances can be advantageous in tablet wet granulation because they reduce the need for added polyvinylpyrrolidone or hydroxypropyl cellulose, but they can also produce batch-to-batch variability in granule density and dissolution. In capsule filling, the dried extract derived from the tincture should be milled to a particle size with D90 ≤ 180 µm and moisture content below 5.0% w/w to prevent plugging of dosator pins or tamping pins. The tincture form itself is not directly filled into hard gelatin capsules because ethanol and water can plasticize the shell and cause embrittlement or leakage.

Compared with synthetic small-molecule veterinary actives, this tincture requires a broader stability evaluation because marker compounds can undergo oxidation, photodegradation, and pH-dependent isomerization. For oral solutions prepared from the tincture, the pH should be adjusted after ethanol removal and the product should be stored in amber glass or opaque high-density polyethylene bottles. A headspace oxygen content below 2.0% v/v is recommended when packaging sensitive marker compounds. Antioxidants such as sodium metabisulfite at 0.05–0.20% w/v may be used only after confirming compatibility with the active constituents; sulfite-based antioxidants can form adducts with certain polyphenols and reduce assay recovery.

Another operational difference is the cleaning validation requirement. Because the tincture contains strongly colored and adhesive botanical constituents, production equipment used for this API should be cleaned with an alkaline detergent wash followed by ethanol or isopropanol rinse. The cleaning acceptance limit is typically based on visual cleanliness plus analytical verification of the marker compound at not more than 10 mg/m² of the next product’s maximum daily dose. Cross-contamination risk in shared multi-product facilities should be assessed under VICH GL18 for veterinary residual solvents and cleaning validation. Dedicated or campaign-based manufacturing is preferred when the API is used in both injectable and oral production lines.

Batch-to-batch variance is controlled through marker standardization. The manufacturer may adjust the tincture with the same extraction solvent or with maltodextrin after drying to bring the marker content within 90.0–110.0% of label claim. This adjustment introduces a difference from unstandardized tinctures: the final ratio of marker compound to total extract may vary even when the primary marker is within specification. For critical dosage forms, the formulator should monitor the fingerprint similarity by HPLC at multiple wavelengths and reject batches whose similarity coefficient falls below 0.95 relative to the registration reference chromatogram. If the tincture is used in an injectable formulation, the presence of high-molecular-weight polysaccharides may create filter-blocking tendencies; filter capacity testing using 0.22 µm polyethersulfone membrane discs should be performed at constant pressure of 1.0 bar and 25°C. Published data for this specific configuration is limited, and filter-compatibility data from the filter manufacturer should not be extrapolated without spiked solution testing.

Specification differences between this product and a direct injectable-grade botanical extract include the requirement for low endotoxin raw water, controlled ethanol denaturation, and terminal bioburden before filtration. The unprocessed tincture is not typically sold as an injectable-ready solution because the ethanol concentration alone would produce injection-site irritation and pharmacological incompatibility. The claim “for Injections” therefore refers to the API’s downstream suitability after solvent removal and formulation, not to direct administration of the tincture. Regulatory filings should explicitly separate the tincture release controls from the finished injectable controls to avoid ambiguity in the API section of the dossier.

Process water used for dilution of the tincture in oral solutions or injectable manufacturing should meet Ph. Eur. Water for Injections quality for parenteral products and Ph. Eur. Purified Water quality for oral solutions. If the final veterinary solution contains propylene glycol or glycofurol as a co-solvent, the ratio of tincture-derived ethanol to co-solvent must be controlled because residual ethanol can alter the dielectric constant and affect the solubility of preservatives such as benzyl alcohol or parabens. The tincture itself may provide antimicrobial activity due to ethanol and botanical constituents, but this is not accepted as proof of preservation under Ph. Eur. 5.1.3 unless the formulation passes challenge testing with Staphylococcus aureus, Pseudomonas aeruginosa, Candida albicans, and Aspergillus brasiliensis.

At production scale, the most frequently observed failure mode with the tincture is incomplete solvent removal before compression or capsule filling. Residual ethanol above 3.0% w/w in the dried granulate can cause adhesion to tablet punch faces, variable tablet weight, and softening of capsule shells during stability storage. A rapid loss-on-drying method at 105°C may overestimate water but not ethanol; therefore, gas chromatographic headspace analysis is required for solvent confirmation. Another recurring issue is marker loss during pregelatinized starch or copovidone wet granulation when the granulation bowl is heated above 70°C; the resulting assay values can decline unevenly across the batch. Operators should monitor granulation end-point by power consumption and not rely solely on granulation time.

Because the tincture can contain suspended lipophilic components, bulk storage should include gentle recirculation or stirring before sampling. Sedimentation during storage can cause top-to-bottom assay variation in drums. If the product is stored at 2–8°C, precipitation of waxes and lipophilic compounds may increase viscosity and clog transfer lines; the tincture should be returned to 20–25°C and mixed for 60 min before dispensing. Filtration of the bulk tincture through a 100 µm in-line strainer before spray application onto carriers reduces nozzle blockage in fluid-bed top-spray systems. For bottom-spray Wurster coating applications, the tincture is generally too high in surface tension; the addition of a surfactant or the use of a rotor-granulator may be required, but this alters release profile and should be evaluated by dissolution testing.

Where the tincture is indicated for use in multiple veterinary species, species-specific safety and residue evaluations must be completed under VICH GL48, GL49, or the applicable residue marker depletion framework. The same API batch may be used across cattle, swine, poultry, and companion animal dosage forms, but withdrawal periods and tolerance values differ. The multi-route claim does not remove the need for separate target animal safety and residue studies, nor does it imply that a premix formulation can be repurposed as an injectable without additional safety and sterility qualification. Regulatory dossiers should define the maximum daily intake of marker compound for each species and dosage form using the assay value from the certificate of analysis.

For tablets, capsules, powders, granules, and premix, the tincture may be replaced by a spray-dried extract if the manufacturer wishes to eliminate ethanol from the solid dosage manufacturing area. However, spray-dried intermediates often have higher hygroscopicity and lower bulk density than the tincture-derived wet-massed granulate. The direct compression of spray-dried extract with microcrystalline cellulose and croscarmellose sodium can yield tablets with friability below 1.0%, but the formulation must be protected from humidity above 60% RH during compression. If the facility cannot maintain low humidity, the tincture route with wet granulation and subsequent drying is preferred because the final granulate is denser and less static-prone.

The product is differentiated from solvent-free botanical extracts by the presence of ethanol as a process solvent and antimicrobial stabilizer. In oral solutions, the residual ethanol from the tincture can contribute to solubilization of lipophilic marker compounds, but it also limits use in neonatal animals and in species with low alcohol dehydrogenase activity. For such formulations, the ethanol is removed and the extract is reconstituted in a non-alcoholic vehicle. This conversion should be performed before addition of suspending agents to avoid viscosity instability caused by ethanol-induced precipitation of xanthan gum or carbomer. A mixing time of 30–60 min after ethanol removal and polymer addition is typically sufficient to achieve full hydration.

The use of Fengman Tincture Veterinary Grade API in any of the seven stated dosage forms requires compatibility testing with the intended packaging. Amber type III glass is acceptable for oral solutions and injectables if the closure system passes moisture and extractables testing. For plastic ampoules or prefilled syringes, the tincture-derived extract may interact with rubber plunger stoppers and promote leaching of zinc dialkyldithiocarbamate accelerators. Extractables should be screened under USP <1663> and USP <1664> conditions using a 30-day hold at 40°C / 75% RH for oral products or inverted storage for injectables. If the extractable profile changes by more than 0.5 µg/mL relative to the placebo, alternative stopper coatings should be considered.

Cleaning validation for shared tablet and capsule equipment should include swab sampling for both the marker compound and total organic carbon. Because polyphenolic residues may darken and adhere to stainless steel surfaces after repeated heat cycles, an alkaline rinse at 60–70°C is more effective than ambient water alone. The final rinse should be tested for pH, conductivity, and visual color. The absence of color does not guarantee absence of active residue; therefore, marker-specific swab limits are required. For injectable lines, the cleaning validation should also include bacterial endotoxin recovery after cleaning, because botanical matrices can interfere with endotoxin removal and mask contamination during the subsequent batch.

Process validation for oral solid dosage forms should include at least 3 consecutive batches at full scale. Blend uniformity samples should be taken from 10 locations, including dead zones near mixer discharge ports. During tableting, in-process controls should include weight at 20-minute intervals, hardness at start-up and every 60 minutes, and disintegration at start-up, middle, and end of the batch. For capsule filling, the coefficient of variation of fill weight should not exceed 3.0% for the target capsule size. For premix, the batch is acceptable when the active marker assay in the final medicated feed is within ±10% of the declared concentration and the blend CV is below 5.0%.

For injectable solution manufacture, the primary critical process parameters are ethanol removal temperature, vacuum level, filtration pressure, and post-filtration bioburden hold time. A maximum hold time of 24 h between filtration and terminal sterilisation is commonly applied unless the validation batch demonstrates longer stability under refrigerated conditions. Sterile filtration of the formulated solution through 0.22 µm polyvinylidene fluoride or polyethersulfone filters requires pre-filtration through 0.45 µm to prevent premature blocking. Bubble point testing should be performed before and after filtration according to ISO 29463 or the filter manufacturer’s integrity test method. If the tincture-derived solution shows high turbidity after pH adjustment, the use of a depth filter with a 0.45 µm cellulosic matrix may be required before the sterilising-grade membrane.

In terms of regulatory filing structure, the API section should describe the tincture manufacturing process from botanical raw material through extraction, concentration, standardization, and packaging. The product specification should be positioned as the release specification for the tincture, not as the finished product specification for any single dosage form. Finished dosage form specifications must be developed separately for tablets, injections, capsules, powders, granules, premix, and solutions because each process introduces different critical quality attributes. A single specification sheet that merges all seven dosage forms is not appropriate for a marketing authorization or registration submission.

The multi-dosage-form designation should not be interpreted as evidence that the tincture is physically suitable for direct use in each form without modification. Instead, it indicates that the active pharmaceutical ingredient can serve as the starting material for the seven listed routes when the required downstream operations are performed. The limitation is important in procurement and quality agreements: the API manufacturer controls the tincture, while the dosage-form manufacturer controls the unit operation steps of ethanol removal, adsorption, drying, milling, blending, sterilisation, and packaging. The technical agreement between the parties should allocate responsibility for assay method transfer, impurity tracking, and stability data sharing according to VICH GL29 and GL45.